Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT02777268 Completed - Healthy Subjects Clinical Trials

Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This was a single centre, open-label, randomised, 5-way crossover study.

NCT ID: NCT02770222 Completed - Healthy Subjects Clinical Trials

A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

Start date: June 2016
Phase: Phase 1
Study type: Interventional

The primary objectives of this 2-part drug interaction study are as follows: - To evaluate the effect of gemfibrozil on the pharmacokinetics (i.e., amount in the blood) of selexipag and its metabolite ACT-333679 (Part I). - To evaluate the effect of rifampicin on the pharmacokinetics of selexipag and its metabolite ACT-333679 (Part II).

NCT ID: NCT02760342 Completed - Healthy Subjects Clinical Trials

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin

Start date: May 15, 2016
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the pharmacokinetic interactions between ASP015K and metformin in healthy non-elderly male subjects.

NCT ID: NCT02756624 Completed - Healthy Subjects Clinical Trials

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Start date: April 2016
Phase: Phase 3
Study type: Interventional

This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution

NCT ID: NCT02753907 Completed - Healthy Subjects Clinical Trials

Impact of an 8-week Linoleic Acid Intake in Soy Oil on Lp-PLA2 Activity in Healthy Adults

Start date: June 2015
Phase: Phase 3
Study type: Interventional

Self-reported healthy participants (n=150) aged 30-65 years with 18.5 kg/m^2 ≤ BMI < 30 kg/m^2 were randomly assigned into three groups: a low linoleic acid (LA, 18:2n-6) group (n=50) replaced 10 mL soy oil with one apple; a medium LA group (control group, n=50) maintained usual food intake; a high LA group (n=50) reduced 1/3 cup of cooked refined rice and consumed 9.9g of soy oil capsules daily as a supplement. Plasma fatty acids and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity were measured at baseline and 8 week alongside other cardiovascular disease risk factors.

NCT ID: NCT02745912 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Start date: April 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of multiple oral doses of naltrexone/bupropion on the pharmacokinetics (PK) of a single oral dose of metformin.

NCT ID: NCT02745860 Completed - Healthy Subjects Clinical Trials

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Start date: June 2016
Phase: Phase 1
Study type: Interventional

Clinical study in healthy adult subjects to compare the adult tablet of selexipag with the tablet developed for children.

NCT ID: NCT02741310 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

Start date: February 22, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to assess the effects of subcutaneous sumatriptan alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan concomitant therapy on resting blood pressure in healthy adults.

NCT ID: NCT02719197 Completed - Healthy Subjects Clinical Trials

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Start date: February 19, 2016
Phase: Phase 1
Study type: Interventional

The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy male adults

NCT ID: NCT02717234 Completed - Healthy Subjects Clinical Trials

Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement

Start date: February 2016
Phase: N/A
Study type: Interventional

To assess the effect of consumption of an oral nutrition supplement on Arginine, a blood marker of nutritional intake